Crescent Biopharma said its board compensation committee approved equity inducement awards granting options for a total of 24,600 ordinary shares to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan. The options have a 10-year term, an exercise price of $9.33, and vest with 25% on the first anniversary of each employee’s start date followed by monthly vesting of 1/48 thereafter, subject to continued service.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657085-en) on February 19, 2026, and is solely responsible for the information contained therein.